Biosimilar and Originator Product in Inflammatory Bowel Diseases: Mind the Gap?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Biosimilar and Originator Product in Inflammatory Bowel Diseases: Mind the Gap?

Published:2019-03-14 Issue:2 Volume:26 Page:246-247
ISSN:0929-8673
Container-title:Current Medicinal Chemistry
language:en
Short-container-title:CMC

Author:

Kotze Paulo Gustavo¹,Danese Silvio²

Affiliation:

1. IBD Outpatient Clinics, Colorectal Surgery Unit Health Sciences Postgraduate Program (PPGCS) Catholic University of Parana (PUCPR), Curitiba, Brazil

2. Department of Biomedical Sciences, IBD Center Department of Gastroenterology, Humanitas Research Hospital Rozzano, Milan, Italy

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry

Reference6 articles.

1. Ribeiro P, Fiorino G, Danese S. The Experience with biosimilars of infliximab in inflammatory bowel disease.

2. Michetti P. Efficacy of infliximab biosimilars in patients with Crohn’s disease.

3. Martelli L, Peyrin-Biroulet L. Efficacy, safety and immunogenicity of biosimilars in inflammatory bowel diseases: A systematic review.

4. Magro F, Coelho R, Peixoto A. Can we extrapolate data from one immune-mediated inflammatory disease to another one?

5. Gulacsi L, Pentek M, Rencz F, Brodszky V, Baji P, Vegh Z, Gecse KB, Danese S, Peyrin-Biroulet L, Lakatos PL. Biosimilars for the management of inflammatory bowel diseases: Economic considerations.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP